Management of elderly diabetic patients in the subacute care setting

Clinics in Geriatric Medicine

Volumn 16, Issue 4, 2000, Pages 833-852

  Lee, Amy ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; C PEPTIDE; INSULIN LISPRO; PSYCHOTROPIC AGENT;

AGED; CONSULTATION; ELDERLY CARE; GERIATRICS; HUMAN; INDWELLING CATHETER; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; INTENSIVE CARE; MEDICAL SPECIALIST; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSIOTHERAPY; REVIEW; UNITED KINGDOM;

EID: 0033771538     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0690(05)70047-1     Document Type: Article

References (70)

1. Impaired glucose tolerance is normalized by treatment with thiazolidinedione troglitazone
2. Biguanides and NIDDM
3. Practical guidelines on the use of insulin lispro in elderly diabetic patients
4. Assessment and management of foot disease in patients with diabetes
5. Role of advanced glycosylation products in complications of diabetes
6. Treatment of type 2 diabetes mellitus with inhaled human insulin: A 3-month multicenter trial
7. Update: Pharmaceuticals and gastric emptying
8. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
10. Quantitative segmental pulse volume recorder: A clinical tool
11. Hypoglycemia in hospitalized patients: Causes and outcomes
12. 2 measurements in health and peripheral arterial occlusive disease
13. Need of insulin therapy in type II diabetes mellitus: A randomized trial
14. Insulin use in NIDDM
15. Oral hypoglycemic agents
16. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve
17. Diabetes mellitus and glucose metabolism in the elderly
18. Acute and chronic complications of diabetes mellitus in older patients
19. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 years
20. Epidemiology of diabetes mellitus among the elderly in the United States
21. The impact of aging on adrenergic receptor function: Clinical and biochemical aspects
22. Role of insulin in management of surgical patients with diabetes mellitus
23. Lispro human insulin: A rapidly absorbed analog of human insulin
24. Aging and diabetes
25. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables
26. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
27. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated type 2 diabetes patients
28. Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase
29. The effect of recombinant human growth hormone on malnourished older individuals
30. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide: Effect on glycemic control, serum lipids and lipoproteins
31. Type 2 diabetes: Glycemic targets and oral therapies for older patients
32. Alpha-glucosidase inhibitors
33. Stimulated C-peptide and glucose levels as metabolic criteria to use insulin treatment in adult-onset type II diabetes
34. Classification of type 2 diabetes by clinical response to metformintroglitazone combination and C-peptide criteria
35. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
36. Enteral/parenteral alimentation
37. Gastric emptying in patients with diabetes mellitus
38. Predicting the need for insulin therapy in late onset (40-69 years) diabetes mellitus
39. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus
40. The management of diabetes mellitus in older individuals
41. An overview of diabetes mellitus in older persons
42. Incidence of diabetes mellitus by clinical type
43. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: A study of two ethnic groups
44. Effects of age on complications in adult onset diabetes
45. Toe blood pressure: A valuable adjunct to ankle pressure measurement for assessing peripheral arterial disease
46. Incidence, outcomes, and cost of foot ulcers in patients with diabetes
47. C-peptide levels as a criterion in treatment of maturity-onset diabetes
48. Glimepiride, a new once-daily sulfonylurea
49. Hospitalization and mortality of diabetes in older adults: A 3-year prospective study
50. Thiazolidinediones in the treatment of insulin resistance in type II diabetes
51. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
52. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with type 2 diabetes inadequately controlled by diet alone
53. Geriatric depression scale: Recent evidence and development of a shorter version
54. Subgroup and pre-protocol analysis of the randomized European Trial on Isolated Hypertension in the Elderly
55. Increased mortality associated with growth hormone treatment in critically ill adults
56. Falls
57. Effects of the short-acting insulin analog {Lys (B28), Pro(B29)} on postprandial blood glucose control
58. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
59. Frequency and importance of postprandial blood pressure reduction in elderly nursing-home patients
60. Diabetic neuropathies
61. Basal C-peptide in the discrimination of type I from type II diabetes
62. General principles of wound healing
63. Effects of a new hypoglycemia agent, repaglinide, on metabolic control in sulfonylurea-treated patients with type 2 diabetes
64. Intensive blood-glucose control with sulfonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
65. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
66. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)
67. Efficacy of atenolol and captopriol in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39)
68. Review: Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome
69. Geriatric depression scale
70. Geriatric cachexia: The role of cytokines